Improved prediction of HLA antigen presentation hotspots: Applications for immunogenicity risk assessment of therapeutic proteins-Reference-Cited by-同舟云学术

Improved prediction of HLA antigen presentation hotspots: Applications for immunogenicity risk assessment of therapeutic proteins

Published:2020-10-19 Issue:2 Volume:162 Page:208-219
ISSN:0019-2805
Container-title:Immunology
language:en
Short-container-title:Immunology

Author:

Attermann Anders Steenholdt¹^ORCID,Barra Carolina¹^ORCID,Reynisson Birkir¹^ORCID,Schultz Heidi Schiøler²,Leurs Ulrike²^ORCID,Lamberth Kasper²^ORCID,Nielsen Morten¹³^ORCID

Affiliation:

1. Department of Health Technology Technical University of Denmark Lyngby Denmark

2. Assay, Analysis & Characterisation Global Research Technologies Novo Nordisk A/S Måløv Denmark

3. Instituto de Investigaciones Biotecnológicas Universidad Nacional de San Martín Buenos Aires Argentina

Funder

Consejo Nacional de Investigaciones Científicas y Técnicas

Foundation for the National Institutes of Health

National Institute of Allergy and Infectious Diseases

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imm.13274

Reference40 articles.

1. Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins

2. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity

3. Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools

4. Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation

5. Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry*

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoantigen-specific T cell help outperforms non-specific help in multi-antigen DNA vaccination against cancer;Molecular Therapy: Oncology;2024-09

2. In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies;mAbs;2024-03-27

3. New light on the HLA-DR immunopeptidomic landscape;Journal of Leukocyte Biology;2024-01-12

4. Immunogenicity risk assessment of synthetic peptide drugs and their impurities;Drug Discovery Today;2023-10

5. Preclinical risk assessment strategy to mitigate the T-cell dependent immunogenicity of protein biotherapeutics: State of the art, challenges and future perspectives;Journal of Pharmaceutical and Biomedical Analysis;2023-09